Eli Lilly | LLY - Current Liabilities


Eli Lilly reported $47B in Current Liabilities for its fiscal quarter ending in September of 2026.





Current Liabilities Change Date
AbbVie USD 43.1B 1.46B Sep/2026
Abbott USD 16.15B 1.66B Sep/2026
ALKERMES USD 651.93M 10.16M Sep/2026
Amgen USD 23.23B 2.27B Sep/2026
AstraZeneca USD 31.27B 286M Sep/2026
Baxter International USD 3.81B 218M Sep/2026
Biogen USD 3.9B 18.7M Sep/2026
Bristol-Myers Squibb USD 18.75B 94M Sep/2026
Coherus Biosciences USD 75.51M 56.82M Jun/2026
Drreddys Laboratories INR 154.49B 13.08B Sep/2026
Eli Lilly USD 47B 745M Sep/2026
Gilead Sciences USD 12B 982M Sep/2026
GlaxoSmithKline GBP 20.72B 814M Sep/2026
Glaxosmithkline GBP 20.72B 1.71B Sep/2026
J&J USD 55.46B 562M Sep/2026
Medtronic USD 11.8B 141M Jun/2026
Merck USD 28.8B 1.07B Sep/2026
Neurocrine Biosciences USD 984.6M 110.1M Sep/2026
Novartis USD 32.52B 777M Sep/2026
Novartis USD 32.52B 1.15B Sep/2026
Novo Nordisk DKK 239.08B 13.92B Jun/2026
Perrigo USD 1.02B 34.4M Sep/2026
Pfizer USD 31.73B 920M Sep/2026
Phibro Animal Health USD 295.79M 20.68M Sep/2026
Prestige Brands USD 168.5M 14.7M Sep/2026
Regeneron Pharmaceuticals USD 6.2B 671.5M Sep/2026
Roche Holding CHF 28.85B 846M Jun/2026
Sanofi EUR 29.77B 2.16B Sep/2026
Sanofi EUR 31.93B 1.92B Jun/2026
United Therapeutics USD 624.3M 16.5M Sep/2026
Zoetis USD 2.68B 621M Sep/2026